DISCUSSION
INTRODUCTION
With a prevalence of 12% among US adults 18 years or older,
Diabetes, predominantly Type II, is one of the most common medical
illnesses we face today1. This number is only set to grow, with a
prevalence of 14% in the US forecasted for 20602. A chronic metabolic
disorder characterized by persistent hyperglycemia, the disease can
lead to hypertension, coronary artery disease, peripheral diabetic
neuropathy, and may progress to high risk of myocardial infarction or
stroke3,4. Thus, there is a large and growing need for effective medical
control of the condition and its symptoms. In this study we compared
the effectiveness of various interventions in controlling Diabetes in
Type II Diabetics currently on insulin.
NATIONAL GUIDELINES

The American Association of Clinical Endocrinology (AACE) Type II
Diabetes Management Algorithm breaks recommended treatment
down into three areas: weight loss, treatment of atherocardiovascular
risk factors, and control of hyperglycemia5. Recommended treatment
for hyperglycemia initially includes administration of metformin, with
the addition of a Glucagon Like Peptide 1 Receptor Antagonist
(GLP1RA) and a Sodium Glucose Co-transporter 2 Inhibitor (SGLT2I)
as needed. If this combination proves insufficient or if a patient
presents with severely high Hemoglobin A1C, insulin is added to the
regimen.
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PURPOSE

This research is intended to determine the rates at which patients at UT
Family Medicine – St. Francis (UTFM–SF) are prescribed the AACE
recommended medications for Type II Diabetes Mellitus (T2DM), and
whether the prescription of these medications is associated with a
patient’s level of glycemic control.
RESEARCH QUESTIONS

1. How many patients with T2DM and on insulin are prescribed
metformin, SGLT2 inhibitors, and/or GLP1R agonists?

Frequency with which Medication Classes are Combined

HbA1C Range

< 7%
(n=40)

> 7%, <
9%
(n=66)

> 9%
(n=128)

Overall (n=234)

Mean Age

49.62

50.17

46.59

48.12

Black/African
American

95%

78.8%

86.7%

85.9% (n=201)

White/Caucasian

5%

19.7%

11.7%

12.8% (n=30)

Race

Asian

-

-

0.8%

0.4%(n=1)

Native American

-

1.5%

-

0.4%(n=1)

Ethnicity

2. What is the frequency of prescription of these medications for those
at different hemoglobin A1C benchmarks (below the clinical
standard as set out by the ADA of 7.0%, above 7.0% but below the
Center for Medicare & Medicaid Services benchmark of 9.0%, and
above 9.0%)?

METHODS
A retrospective chart review was conducted, using the records of
patients seen within the previous four years at UT Family Medicine
who had visits labeled with ICD 10 codes for Type 2 Diabetes Mellitus
(E11) and long-term current use of insulin (Z79.4). Only those between
the ages of 18 and 65 were considered for analysis.
Of the 272 record numbers meeting this criteria, 8 were for fictional
patients, 5 belonged to patients with no chart history of insulin use, 4
were no longer linked to a patient record, and 1 belonged to a patient
with type 1 diabetes. An additional 16 patients’ records were excluded
because they did not contain an HbA1C measurement, and 4 were
excluded because their most recent HbA1C value was more than 4
years old.
Data was manually abstracted from the remaining 234 patient
records on the NextGen electronic medical record system and
transferred to SPSS 28 for storage and analysis. 26 patients within this
pool were no longer prescribed insulin, so this study only utilized data
that had been recorded by the date on which their prescription was
discontinued.

LIMITATIONS
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RESULTS
DEMOGRAPHICS

Hispanic/Latino

-

3%

-

0.9% (n=2)

Male

25%

24.2%

20.3%

22.2% (n=52)

Female

75%

75.8%

79.7%

77.8% (n=182)

Gender

Table 1: Demographics of patients at UTFM–SF with T2DM on
long-term insulin, broken down by level of glycemic control.
Patients’ three most recent HbA1C values were averaged in order
to assign them to the HbA1C range categories.

a) Frequency of Prescription of Metformin

CURRENT STUDY

Figure 1: Breakdown of the frequency at which patients of varying
levels of glycemic control are prescribed combinations of the three
antidiabetic medication classes studied: metformin, SGLT2
inhibitors, and/or GLP1-receptor agonists.

Metformin Prescription Trends
HbA1C Range

< 7%
(n=40)

> 7%, < 9%
(n=66)

> 9%
(n=128)

Metformin previously prescribed, then
discontinued

25%
(n=10)

27.3%
(n=18)

25%
(n=32)

Percent of above population that
trialed extended-release
metformin before discontinuation

50%
(n=5)

38.9%
(n=7)

37.5%
(n=12)

Never prescribed metformin

25%
(n=10)

18.8%
(n=24)

Most common starting dose

1000 mg/day
(n=13)

21.2%
(n=14)
1000
mg/day
(n=24)

1000 mg/day
(n=500)

Frequency of HbA1C Checks
HbA1C Range

< 7%
(n=40)

> 7%, < 9%
(n=66)

> 9%
(n=128)

Mean number of days between each HbA1C check

270.5

197.4

251.4

330.3

129.3

271.2

161

159

170.5

Standard deviation
Median number of days between each HbA1C check

Distribution of HbA1C Check Frequency

c) Frequency of Prescription of GLP1 Receptor Agonists

ACKNOWLEDGEMENTS
We would like to thank Dr. Matthews, Dr. Busby, Dr. Pratt Eugene
and Dr. Johnson for their guidance and recommendations on this
project. We would also like to thank Dr. Miller and The UT Saint
Francis Family Medicine Clinic for allowing us to work on this project
at their facility.
Figures 1a-c: Frequency at which patients at UTFM–SF are
prescribed three main classes of medication for the treatment of
T2DM, stratified by level of glycemic control.

• The reason for patient discontinuation of a drug was not able to be
considered in this study, as a reason was usually not supplied in the
charts reviewed. Additionally, the presence of chronic kidney
disease was not considered. Metformin is contraindicated for CKD
stage 4 patients, and therapy modificattions are dconsidered for
stage 3b, thus this could account for some of the low prescription
rates.
• Only patient history from their time at UT Family Medicine was
reviewed, as it was the only data accessible to researchers. It is
possible that some patients may have been trialed on metformin,
SGLT2 inhibitors, and/or GLP1R agonists before starting care with
UT Family Medicine.

RECOMMENDATIONS

Table 3: Further analysis of trends in metformin prescription and
discontinuation.

b) Frequency of Prescription of SGLT2 Inhibitors

The analysis conducted was most notable for revealing that there
are limited differences between patients of varying levels of glycemic
control with regards to the classes and number of antidiabetic
medications prescribed. There was a difference between the <7% and
the >9% groups of less than 15% with regards to percent prescribed
metformin, SGLT2 inhibitors, GLP1 receptor agonists. A similar
proportion of each group were also not currently taking any
medications of the classes.
Additionally, the data do not reflect an increase in the intensity of
treatment or monitoring for patients with higher HbA1C results. A
higher proportion of patients in the >7%,<9% group was on a
combination of all three medication classes than with patients in the
>9% group, and the median number of days between HbA1C checks
was very similar between all three groups.
Within all three groups, over 40% of patients were not currently
prescribed metformin, and around 20% in each group had no chart
history of a metformin prescription—alarming considering that the
ADA considers metformin to be part of the first-line treatment for
T2DM.6 The data reveal increased trialing of the extended-release
formulation as a potential recourse, as 62.5% of those in the highest
A1C group who stopped taking metformin had not trialed this format.

Table 2 and Figure 3: Distribution of the frequency with which
patients of varying levels of glycemic control had their HbA1C
checked. Box-and-whiskers chart displays median, quartiles, and
outliers (defined as removed from the first or third quartile by
greater than 1.5 times the interquartile range)

The following recommendations are given for maximizing reduction of
patient HbA1C in Type II Diabetics on insulin:
• All eligible patients with elevated HbA1C levels should be trialed
on concurrent use of metformin, an SGLT2 inhibitor, and a GLP1R
agonist, and their new HbA1C levels monitored. Currently, only
12.1% in the HbA1C >7%,<9% group and just 6.3% in the >9% group
are on all three medication classes.
• Patient HbA1C should be checked quarterly, in line with with the
American Diabetes Association recommendations.7
• When beginning a patient on metformin, choosing a low dose and
an extended-release option before slowly increasing dosages.
• Patients should be appropriately counselled on potential side effects
of medications on initial prescription and at follow up appointment.
FUTURE STUDIES ON EFFICACY OF T2DM TREATMENTS

Suggested next steps include:
• Comparison of different drugs in each class (for example, different
SGLT2 inhibitors), to see if there is a statistically significant
difference between which drugs are more likely to be discontinued
by the patient; comparison of starting dosages of metformin and
their correlation to patient intolerance/discontinuation; and inquiry
into which combination of the three classes leads to the most
significant drop in HbA1C in patients.
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